{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:09:58Z","timestamp":1783930198767,"version":"3.55.0"},"reference-count":26,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Gemcitabine plus cisplatin (GemCis) has been served as an important first-line chemotherapy backbone for unresectable locally advanced or metastatic biliary tract cancer (BTC). However, cisplatin is unsuitable for all patients. Gemcitabine plus carboplatin (GemCarbo) is frequently used as an alternative, but direct comparative data remain limited. We retrospectively review patients with unresectable locally advanced or metastatic BTC who received first-line GemCis or GemCarbo at Songklanagarind Hospital between 2011 and 2025. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and selected laboratory-based safety outcomes. Propensity score matching was applied to reduce baseline treatment selection bias. Among 154 eligible patients, 95 received GemCis and 59 received GemCarbo. In the overall cohort, median OS was 8.44 months with GemCarbo and 9.82 months with GemCis (HR, 1.18; 95% CI, 0.82\u20131.70; p = 0.382). After propensity score matching, median OS was 8.44 months with GemCarbo and 11.63 months with GemCis (HR, 1.26; 95% CI, 0.84\u20131.90; p = 0.271). Median PFS was 4.27 and 5.75 months (HR, 0.91; 95% CI, 0.62\u20131.33; p = 0.617). ORR and DCR were comparable among evaluable patients. Increased serum creatinine was more frequent with GemCis, whereas hematologic toxicities were comparable. GemCarbo showed no statistically significant difference in OS or PFS compared with GemCis, suggesting that it may be considered as an alternative when cisplatin is unsuitable. However, prospective validation is warranted.<\/jats:p>","DOI":"10.3390\/life16071150","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:28:27Z","timestamp":1783927707000},"page":"1150","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Choosing the Platinum Partner in Advanced Biliary Tract Cancer: A Propensity Score\u2013Matched Real-World Comparison of Gemcitabine Plus Carboplatin Versus Gemcitabine Plus Cisplatin"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1265-7459","authenticated-orcid":false,"given":"Jirapat","family":"Wonglhow","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9787-270X","authenticated-orcid":false,"given":"Patrapim","family":"Sunpaweravong","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9788-3692","authenticated-orcid":false,"given":"Chirawadee","family":"Sathitruangsak","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0593-4385","authenticated-orcid":false,"given":"Arunee","family":"Dechaphunkul","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5962-4112","authenticated-orcid":false,"given":"Panu","family":"Wetwittayakhlang","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/liv.14095","article-title":"Cholangiocarcinoma: Epidemiology and risk factors","volume":"39","author":"Khan","year":"2019","journal-title":"Liver Int."},{"key":"ref_2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA. Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: The next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/MOG.0b013e3282fbf9b3","article-title":"Cholangiocarcinoma: Lessons from Thailand","volume":"24","author":"Sripa","year":"2008","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.6004\/jnccn.2025.0042","article-title":"Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology","volume":"23","author":"Benson","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"104003","DOI":"10.1016\/j.esmoop.2024.104003","article-title":"ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer","volume":"10","author":"Vogel","year":"2025","journal-title":"ESMO Open"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): Updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jhep.2025.05.003","article-title":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","volume":"83","author":"Oh","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1476-5829.2007.00142.x","article-title":"Cisplatin: A review of toxicities and therapeutic applications","volume":"6","author":"Barabas","year":"2008","journal-title":"Vet. Comp. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4212\/cjhp.v70i2.1641","article-title":"Risk Factors for Nephrotoxicity Associated with Cisplatin","volume":"70","author":"Almanric","year":"2017","journal-title":"Can. J. Hosp. Pharm."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Baraka, B., Ponda, D.J., Hanna, J., Gomez, D., Aithal, G., and Arora, A. (2025). Efficacy and Toxicity Profile of Carboplatin\/Gemcitabine Chemotherapy in Locally Advanced or Metastatic Biliary Tract Cancer: A Single UK Centre Experience. Cancers, 17.","DOI":"10.3390\/cancers17193102"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1477-2574.2010.00197.x","article-title":"Gemcitabine with carboplatin for advanced biliary tract cancers: A phase II single institution study","volume":"12","author":"Williams","year":"2010","journal-title":"HPB"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.lungcan.2019.07.010","article-title":"Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis","volume":"135","author":"Griesinger","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"Ovarian Cancer Study Group. A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"Meier","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1470-2045(10)70275-8","article-title":"A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy","volume":"12","author":"Galsky","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"103706","DOI":"10.1016\/j.esmoop.2024.103706","article-title":"Evolving therapeutic landscape of advanced biliary tract cancer: From chemotherapy to molecular targets","volume":"9","author":"Kehmann","year":"2024","journal-title":"ESMO Open"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"114046","DOI":"10.1016\/j.ejca.2024.114046","article-title":"Unresectable biliary tract cancer: Current and future systemic therapy","volume":"203","author":"Zhang","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/sj.bjc.6603648","article-title":"Chemotherapy in advanced biliary tract carcinoma: A pooled analysis of clinical trials","volume":"96","author":"Eckel","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.21037\/jgo-23-155","article-title":"Real-world treatment patterns and survival outcomes for treated biliary tract cancer patients using administrative databases in Ontario","volume":"14","author":"Seung","year":"2023","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"106939","DOI":"10.1016\/j.ejps.2024.106939","article-title":"Advances in understanding cisplatin-induced toxicity: Molecular mechanisms and protective strategies","volume":"203","author":"Elmorsy","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4103\/ijc.IJC_622_17","article-title":"Gemcitabine with carboplatin for advanced intrahepatic cholangiocarcinoma: A study from North India Cancer Centre","volume":"55","author":"Babu","year":"2018","journal-title":"Indian J. Cancer"},{"key":"ref_25","first-page":"10732748251397096","article-title":"Effectiveness of Chemotherapy Plus Immunotherapy and Molecular Alterations in Advanced Biliary Tract Cancer: Real-World Evidence From a Single-Center Australian Cohort","volume":"32","author":"Wonglhow","year":"2025","journal-title":"Cancer Control J. Moffitt Cancer Cent."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Liberko, M., and Soumarova, R. (2026). Treatment of biliary tract cancer-essentials for clinical practice. Front. Oncol., 16.","DOI":"10.3389\/fonc.2026.1750154"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/7\/1150\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:38:20Z","timestamp":1783928300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/7\/1150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":26,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["life16071150"],"URL":"https:\/\/doi.org\/10.3390\/life16071150","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]}}}